RARE Filings — Ultragenyx Pharmaceutical Inc. - FilingSpy
RARE
Ultragenyx Pharmaceutical Inc.
A biopharmaceutical company that develops and sells treatments for rare and ultra-rare genetic diseases, many of which had no approved therapy before. Its marketed medicines include CRYSVITA for a bone disorder called X-linked hypophosphatemia and MEPSEVII for a lysosomal storage disease. Founded in 2010 by pediatric geneticist Emil Kakkis, the company's name blends "ultra" (for ultra-rare diseases) with "genyx" (for genetics), and it trades on the stock market under the ticker symbol RARE.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -155.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.